The consolidated opinions of the Committees for Risk Assessment and Socio-economic Analysis for uses of the following substances are now available:

• 19 uses of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated by Baxter AG and Baxalta Belgium Manufacturing SA; by Yposkesi; by Vetter Pharma-Fertigung GmbH & Co. KG; by Sanquin Reagents B.V; by LFB BIOMEDICAMENTS; by Abbott Ireland, Abbott GmbH and Abbott Diagnostics GmbH; by Lilly France and Eli Lilly Italia S.p.A.; by AGC Biologics A/S and AGC Biologics GmbH; by MERCK MILLIPORE LIMITED; use by Wallac Oy; by BioMérieux SA;
• five uses of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated and 4-nonylphenol, branched and linear, ethoxylated by Beckman Coulter Ireland, Beckman Coulter GmbH, Immunotech s.r.o., Immunotech S.A.S., Beckman Coulter France S.A.S., BC Distribution B.V.,Beckman Coulter Česká republika s.r.o., Beckman Coulter UK, Beckman Coulter S.L.U and Beckman Coulter SPA Italy;
• three uses of pitch, coal tar, high-temp. by BILBAINA DE ALQUITRANES, S.A.; by Industrial Quimica del Nalon, S.A.; by DEZA a.s.;
• two uses of pitch, coal tar, high-temp. and anthracene oil by BILBAINA DE ALQUITRANES, S.A.; and by Koppers Denmark ApS.